title: Re: early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial.
authors.forename: Luca
authors.initials: L
authors.lastname: Testa
authors.forename: William
authors.initials: W
authors.lastname: Van Gaal
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Biondi-Zoccai
authors.forename: Antonio
authors.initials: A
authors.lastname: Abbate
authors.forename: Graziana
authors.initials: G
authors.lastname: Trotta
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Agostoni
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects; D001384:Azetidines / Q000009:adverse effects; D001596:Benzylamines / Q000009:adverse effects; D001777:Blood Coagulation; D001779:Blood Coagulation Factors / Q000378:metabolism*; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood*; D017202:Myocardial Ischemia / Q000097:blood*; D010446:Peptide Fragments / Q000378:metabolism; D011498:Protein Precursors / Q000378:metabolism; D011516:Prothrombin / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D001779:Blood Coagulation Factors; D010446:Peptide Fragments; D011498:Protein Precursors; C426686:ximelagatran; C029733:prothrombin fragment 1; C044183:prothrombin fragment 2; D011516:Prothrombin